Tetanus-diphtheria toxoids (Td)

Phase 1Biologic

CCenters for Disease Control and Prevention

Tetanus-diphtheria toxoids (Td) is one of 18 biologic programs targeting Diphtheria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiphtheriaActive, not recruiting

DiphtheriaPhase 1

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Diphtheria

#DrugCompanyPhaseTrials

BCG Vaccine

GGynecologic Oncology Group

Approved

1 2

GSK 257049

GSK

Phase 3

2 3

Infanrix

GSK

Phase 3

1 4

Havrix

GSK

Phase 3

1 5

Rsvpref3 Vaccine

GSK

Phase 2

1 6

Acthib

GSK

Phase 3

1 7

REVAXIS

Sanofi

Phase 3

1 8

Vi-Polysaccharide Vaccine

Novartis

Phase 3

1 9

Dtacp

CChangchun BCHT Biotechnology Co.

Phase 3

2 10

Dtap-IPV Combination Vaccine

Boryung Pharmaceutical Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diphtheria1 trial

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine

Completed·CCenters for Disease Control and Prevention·Phase 1·NCT00164411·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tetanus-diphtheria toxoids (Td). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetanus-diphtheria toxoids (Td) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetanus-diphtheria toxoids (Td). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centers for Disease Control and Prevention company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCenters for Disease Control and Prevention

Tetanus-diphtheria toxoids (Td)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diphtheria1 trial

References

Drug Info

Quick Facts

Related News